Jasper Therapeutics, Inc.JSPRNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank40
3Y CAGR-47.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-47.8%/yr
Annual compound
Percentile
P40
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
1 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2024 | 19.57% |
| 2023 | 3.06% |
| 2022 | 45.19% |
| 2021 | 137.75% |
| 2020 | 339.56% |
| 2019 | 0.00% |